Off-label use of intravitreal bevacizumab has become a widespread treatment for neovascular age-related macular degeneration [REF].
In October 2006, the National Eye Institute (NEI) of the National Institutes of Health (NIH) announced that it would fund a comparative study trial of ranibizumab and bevacizumab to assess the relative efficacy and ocular adversity in treating wet AMD.